Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 6/20 | 0.53 |
| ▸ | F11 | P03951 | 1/20 | 0.49 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.49 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.49 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.49 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.49 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.49 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.49 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.49 |
| ▸ | XDH | P47989 | 1/20 | 0.49 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28788974 | 0.89 | AKR1C3 (0.51) | MAPK14F11PIN1SLC22A12XDH | |
| SCHEMBL1231896 | 0.84 | SLC22A12 (0.56) | MAPK14SLC22A12GRIK1GRIA1GRIA2 | |
| SCHEMBL6655408 | 0.81 | MAPK14 (0.80) | MAPK14NR1H4 | |
| SCHEMBL2039607 | 0.81 | SLC22A12 (0.53) | MAPK14SLC22A12GRIK1GRIA1GRIA2 | |
| SCHEMBL26464789 | 0.80 | GRIK1 (0.55) | GRIK1GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL28788970 | 0.80 | AKR1C3 (0.50) | F11PIN1SLC22A12XDHPDE4A | |
| SCHEMBL5529069 | 0.80 | XDH (0.62) | F11PIN1SLC22A12XDHPDE4A | |
| SCHEMBL2744081 | 0.80 | GRIK1 (0.56) | GRIK1GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL28788990 | 0.80 | ROCK2 (0.51) | SLC22A12XDHMRGPRX4PTGDR2 | |
| SCHEMBL2034067 | 0.79 | XDH (0.65) | SLC22A12GRIA2GRIA4XDHPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120196849-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2012-08-02 | — | — | US | claimed |
| US-20100197659-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOD PATHWAY MODULATORS | IRM LLC (BM) | 2010-08-05 | — | — | US | claimed |
| US-20090203666-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2009-08-13 | — | — | US | claimed |
| EP-3023097-A1 | SMOOTHENED ANTAGONISM FOR THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS | Novartis AG (CH) | 2016-05-25 | — | — | EP | disclosed |
| US-20150209365-A1 | Methods and Compositions for Treating Luekemia | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | disclosed |
| US-20150025074-A1 | METHODS AND COMPOSITIONS FOR TREATING SOLID TUMORS AND OTHER MALIGNANCIES | BUONAMICI SILVIA (US) | 2015-01-22 | — | — | US | disclosed |
| US-20140200217-A1 | SMOOTHENED ANTAGONISM FOR THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS | DORSCH MARION (US) | 2014-07-17 | — | — | US | disclosed |
| US-8778927-B2 | Smoothened antagonism for the treatment of hedgehog pathway-related disorders | NOVARTIS AG (CH) | 2014-07-15 | — | — | US | disclosed |
| US-8507471-B2 | Biphenylcarboxamide derivatives as hedgehod pathway modulators | IRM LLC (BM) | 2013-08-13 | — | — | US | disclosed |
| EP-2617414-A2 | Smoothened antagonism for the treatment of hedgehog pathway-related disorders | Novartis AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| US-20120329798-A1 | METHODS AND COMPOSITIONS FOR TREATING LUEKEMIA | COPLAND MHAIRI (GB) | 2012-12-27 | — | — | US | disclosed |
| EP-2464423-A1 | METHODS AND COMPOSITIONS FOR TREATING LEUKEMIA | Novartis AG (CH) | 2012-06-20 | — | — | EP | disclosed |
| US-8178563-B2 | Compounds and compositions as hedgehog pathway modulators | IRM LLC (BM) | 2012-05-15 | — | — | US | disclosed |
| WO-2011062939-A1 | METHODS AND COMPOSITIONS FOR TREATING SOLID TUMORS AND OTHER MALIGNANCIES | NOVARTIS AG (CH) | 2011-05-26 | — | — | WO | disclosed |
| US-20100197659-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOD PATHWAY MODULATORS | IRM LLC (BM) | 2010-08-05 | — | — | US | disclosed |
| EP-2162190-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2010-03-17 | — | — | EP | disclosed |
| US-20090203666-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2009-08-13 | — | — | US | disclosed |
| EP-2021328-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2009-02-11 | — | — | EP | disclosed |
| WO-2008154259-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2008-12-18 | — | — | WO | disclosed |
| WO-2007131201-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025074-A1 | METHODS AND COMPOSITIONS FOR TREATING SOLID TUMORS AND OTHER MALIGNANCIES | MTOR, ULK1, HRAS | MAPK14 816/4885F11 4661/4885PIN1 3024/4885 |
| US-20150209365-A1 | Methods and Compositions for Treating Luekemia | MCL1, ABL1, BCR | MAPK14 1933/4885F11 4116/4885PIN1 3166/4885 |
| US-20100197659-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOD PATHWAY MODULATORS | GLI1, SHH, GLI2 | MAPK14 2353/4885F11 4726/4885PIN1 613/4885 |
| US-20090203666-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | GLI1, SHH, SMO | MAPK14 1601/4885F11 3730/4885PIN1 2149/4885 |
| US-20120196849-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | GLI1, SHH, SMO | MAPK14 1601/4885F11 3730/4885PIN1 2149/4885 |
| US-20120329798-A1 | METHODS AND COMPOSITIONS FOR TREATING LUEKEMIA | MCL1, ABL1, BCR | MAPK14 1933/4885F11 4116/4885PIN1 3166/4885 |
| US-20140200217-A1 | SMOOTHENED ANTAGONISM FOR THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS | GLI1, SHH, SMO | MAPK14 1199/4885F11 4046/4885PIN1 2543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.